SCHEMBL21669352

SCHEMBL21669352

CCOC(O)C(NC(C)=O)c1ccc(OC(=O)CCS(=O)(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ESR1 P03372 1/20 0.36
HIF1A Q16665 1/20 0.36
ACACB O00763 8/20 0.36
ACACA Q13085 4/20 0.35
OPRK1 P41145 1/20 0.34
MEN1 O00255 2/20 0.32
BCL9 O00512 1/20 0.32
CTNNB1 P35222 1/20 0.32
ELANE P08246 1/20 0.32
GPR88 Q9GZN0 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
GAA P10253 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24282722 0.89 KMT2A (0.39) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669311 0.89 KMT2A (0.42) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669220 0.87 KMT2A (0.45) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669232 0.86 PPARG (0.39) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669296 0.86 KMT2A (0.38) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669233 0.83 CA1 (0.43) KMT2ALMNAMEN1ELANECYP3A4
SCHEMBL21669324 0.83 KMT2A (0.39) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669317 0.81 KMT2A (0.41) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669302 0.79 KMT2A (0.41) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL21669212 0.76 KMT2A (0.43) KMT2AALDH1A1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed
WO-2020028348-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 KMT2A 3892/4885ALDH1A1 591/4885LMNA 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.